Disease block
C60-C63 – Bösartige Neubildungen der männlichen Genitalorgane
- Chapter II: Neubildungen
27Decisions
43Patient groups
Added benefit by patient group
- Considerable12
- Minor3
- Not proven27
- Lesser benefit1
Diseases in this disease block
- C60 Bösartige Neubildung des Penis 5 decisions
- C61 Bösartige Neubildung der Prostata 27 decisions
- C62 Bösartige Neubildung des Hodens 5 decisions
- C63 Bösartige Neubildung sonstiger und nicht näher bezeichneter männlicher Genitalorgane 5 decisions
Decisions, newest first
Each decision lists only the patient groups coded with a disease in this disease block.
- 2026-09-03AkeegaNiraparib/AbirateronacetatNot proven: 2 of 2 patient groups
- 2026-02-19NubeqaDarolutamidNot proven
- 2025-10-16AugtyroRepotrectinibNot proven: 2 of 2 patient groups
- 2025-01-16LocametzGozetotidConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2024-11-07RetsevmoSelpercatinibNot proven
- 2024-08-15TalzennaTalazoparibNot proven: 2 of 3 patient groupsLesser benefit: 1 of 3 patient groups
- 2024-05-02AkeegaNiraparib/AbirateronacetatConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2024-02-06RozlytrekEntrectinibNot proven
- 2023-09-21NubeqaDarolutamidConsiderable
- 2023-07-06LynparzaOlaparibConsiderable: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2023-07-06Pluvicto(177Lu)LutetiumvipivotidtetraxetanConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2023-04-06OrgovyxRelugolixNot proven: 5 of 5 patient groups
- 2021-11-19XtandiEnzalutamidNot proven
- 2021-06-03LynparzaOlaparibConsiderable
- 2021-02-18RozlytrekEntrectinibNot proven
- 2020-11-05XtandiEnzalutamidMinor
- 2020-10-15NubeqaDarolutamidConsiderable
- 2020-10-01ErleadaApalutamidMinor
- 2020-08-20ErleadaApalutamidNot proven
- 2020-04-02VitrakviLarotrectinibNot proven
- 2019-10-17XofigoRadium-223-dichloridNot proven: 2 of 2 patient groups
- 2018-06-07ZytigaAbirateronacetatConsiderable
- 2015-06-18XtandiEnzalutamidConsiderable
- 2014-02-20XtandiEnzalutamidConsiderable
- 2013-07-04ZytigaAbirateronacetatConsiderable
- 2012-03-29ZytigaAbirateronacetatConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2012-03-29JevtanaCabazitaxelMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
Data status: 2026-10-29